Cargando…
Novel iridium (III)-derived organometallic compound for the inhibition of human platelet activation
Since cisplatin achieved clinical success, transition metal platinum (Pt) drugs have been effectively used for the treatment of cancer. Iridium (Ir) compounds are considered to be potential alternatives to Pt compounds, as they possess promising anticancer effects with minor side effects. Platelet a...
Autores principales: | Shyu, Kou-Gi, Velusamy, Marappan, Hsia, Chih-Wei, Yang, Chih-Hao, Hsia, Chih-Hsuan, Chou, Duen-suey, Jayakumar, Thanasekaran, Sheu, Joen-Rong, Li, Jiun-Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846649/ https://www.ncbi.nlm.nih.gov/pubmed/29436605 http://dx.doi.org/10.3892/ijmm.2018.3472 |
Ejemplares similares
-
Novel iridium (III)-derived organometallic compound for the inhibition of human platelet activation
por: Shyu, Kou-Gi, et al.
Publicado: (2019) -
New Therapeutic Agent against Arterial Thrombosis: An Iridium(III)-Derived Organometallic Compound
por: Hsia, Chih-Wei, et al.
Publicado: (2017) -
Ir-6: A Novel Iridium (III) Organometallic Derivative for Inhibition of Human Platelet Activation
por: Shyu, Ren-Shi, et al.
Publicado: (2018) -
Esculetin, a Coumarin Derivative, Prevents Thrombosis: Inhibitory Signaling on PLCγ2–PKC–AKT Activation in Human Platelets
por: Hsia, Chih-Wei, et al.
Publicado: (2019) -
Novel Therapeutic Agent against Platelet Activation In Vitro and Arterial Thrombosis In Vivo by Morin Hydrate
por: Hsia, Chih-Wei, et al.
Publicado: (2018)